|
|
|
| The necessity for biotechnology major of medical college for set up pharmacogenomics |
| LI Meng1 DUAN Ran2 JIANGXinju2 GUO Yanhai1 LU Zifan1 YUAN Yuan3 |
1.School of Pharmacy, the Fourth Military Medical University, Shaanxi Province, Xi'an 710032, China;
2.The brigade of undergraduates, the Fourth Military Medical University, Shaanxi Province, Xi'an 710032, China;
3.Deparment of Vasculocardiology, Xijing Hospital affiliated to the Fourth Military Medical University, Shaanxi Province, Xi'an 710032, China |
|
|
|
Abstract Pharmacogenomics is a new discipline which intend to go deep and extend of genomics in the field of pharmacy. Pharmacogenomics can not only helps people better understand the causes of different individuals differences in drug reactions, but also directs the development and clinical use of new drugs. With the introduction of the concept of "precision medicine" and the arrival of the era of "personalized medicine", pharmacogenomics is becoming more and more concerned and is gradually enter clinical application. On the other hand, biotechnology has been widely used in diagnosis, pharmaceutical and other fields in recent years, medical and pharmaceutical colleges and universities have set up biotechnology major, with a view to training pharmaceutical professionals for laboratory, pharmacy and new drug development. However, most biotechnology majors currently have very few pharmacogenomics, which is very bad for cultivating talents in the era of "individualized medicine". Based on the research content and practical application of pharmacogenomics, this paper analyzes the necessity of pharmacogenomics in the specialty of biotechnology in medical and pharmaceutical colleges, which provide information for improving the curriculum system of biotechnology.
|
|
|
|
|
|
[1] 姜远英.药物基因组学[M].北京：人民卫生出版社，2006：45-89.
[2] Mancinelli L，Cronin M，Sadée W.Pharmacogenomics：the promise of personalized medicine [J]. AAPS Pharm Sci， 2000，2（1）：e4-e10.
[3] Lu YF，Goldstein DB，Angrist M，et al. Personalized medicine and human genetic diversity [J]. Cold Spring Harb Perspect Med，2014，4（9）：008581-008588.
[4] Huser V，Sincan M，Cimino JJ，et al. Developing genomic knowledge bases and databases to support clinical management：current perspectives [J]. Pharmgenomics Pers Med，2014，9（7）：275-283.
[5] Owen RP，Klein TE，Altman RB. The education potential of the pharmacogenetics and pharmacogenomics knowledge base （PharmGKB） [J]. Clin Pharmacol Ther，2007， 82（4）：472-475.
[6] Auffray C，Charron D，Hood L. Predictive，preventive，personalized and participatory medicine：back to the future [J]. Genome Med，2010，2（8）：57-59.
[7] 张伟，贺毅憬，周宏灏.遗传药理学的学科发展与未来[J].中国临床药理学与治疗学，2008，13（9）：36-39.
[8] Clayton TA，Lindon JC，Cloarec O，et al. Pharmaco-metabonomic phenotyping and personalized drug treatment [J]. Nature，2006，440（7087）：1073-1077.
[9] Giacomini KM，Brett CM，Altman RB，et al. The pharmacogenetics research network：from SNP discovery to clinical drug response [J]. Clin Pharmacol Ther，2007，81（3）：328-345.
[10] International HapMap Consortium. A second generation human haplotype map of over 3.1 million SNPs [J]. Nature，2007，449（7164）：851-861.
[11] Cooper GM，Johnson JA，Langaee TY，et al. A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose [J]. Blood，2008， 112（4）：1022-1027.
[12] Finkelman BS，French B，Bershaw L，et al. Predicting prolonged dose titration in patients starting warfarin [J]. Pharmacoepidemiol Drug Saf，2016，25（11）：1228-1235.
[13] US Food & Drug Administration.Table of Pharmacogenomic Biomarkers in Drug Labeling [EB/OL].（2017-10-03）[2017-11-05] http：//www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm083378.htm.
[14] Lynch TJ，Bell DW，Sordella R，et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib [J]. N Engl J Med，2004，350（21）：2129-2139.
[15] Riely GJ，Pao W，Pham D，et al. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib [J]. Clin Cancer Res，2006，12（3）：839-844.
[16] 龙健，乙引.生物技术专业课程体系教学创新探索[J].中国生物工程杂志，2005，33（S1）：221-223.
[17] 张敏，陈健民，管天球，等.地方本科院校生物工程专业应用型人才培养探索[J].湖南科技学院学报，2009，30（4）：97-99.
[18] 张木，魏于全.医药生物技术研究与产业化进展[J].生物工程进展，2002，22（1）：32-34.
[19] 朱洁.大学生物技术专业基因工程课程考试改革的思考[J].中国校外教育，2017，22（28）：11-13.
[20] 温家根，周宏灏，张伟.药物基因组学在药物研发中的转化与应用[J].中国药理学通报，2013，29（4）：445-449. |
|
|
|
